Neurosciences

Overview

The Neuroscience area is consolidating its position as one of the largest clusters of research labs working on neurological diseases across Europe. At present, the area comprises 14 groups with more than one hundred fully dedicated researchers in close contact with top clinicians in the hospital. These research groups pursue a better and multifaceted understanding of the etiopathogenic mechanisms underlying a large variety of mostly adult but also pediatric neurological disorders including stroke, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, primary headaches, epilepsy, neuromuscular disorders, and also neurosurgical and psychiatric pathologies. The area also integrates groups involved in neuroimaging, analysis and interpretation of high-throughput data, and gene therapy strategies to target inflammatory and neurodegenerative neurological conditions.

Publications

276

total

1952

impact factor

7.07

average impact factor

Group Leader: Josep Gámez

team

group-zoom

zoom

group-download

download

The main lines of research of the group have focused on determining the genetic risk factors that influence the phenotypes of Amyotrophic Lateral Sclerosis (ALS), Myasthenia gravis (MG) and other neuromuscular diseases, based on a model of medicine translational research.

The group has described for the first time the p.A5V mutation of the SOD1 gene associated with ALS in a family from Spain. Also it has reported the existence of prionopathy in patients with ALS and FTD.

The group has identified new haplotypes of the HLA complex as risk factors in MG in the Spanish population, and it has incorporated a new PhD thesis project investigating the role of immunological abnormalities in patients with Parkinson’s disease associated with MG. Also it has described forms of Parkinsonism in patients with Spastic Paraplegia type 7.

Dr. Gamez is the only Spanish ALS specialist who is member of the ALSUNTANGLED network and he has collaborated in a Consensus-guide for management of MD2 (PMID:31583190)

10

total

39

impact factor

3^.94

average impact factor

SELECTED ARTICLES

Gamez J, Salvadó M, Reig N, Suñé P, Casasnovas C, Rojas-Garcia R, Insa R.
Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study.
Amyloid. 2019 Jun;26(2):74-84.
DOI: 10.1080/13506129.2019.1597702.
IF: 4.919
Gamez J, Salvadó M, Carmona F, de Nadal M, Romero L, Ruiz D, Jáuregui A, Martínez O, Pérez J, Suñé P, Deu M.
Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis.
Ther Adv Neurol Disord. 2019 Jul 17;12:1756286419864497.
doi: 10.1177/1756286419864497.
IF: 5.0
Garcia C, Vidal-Taboada JM, Syriani E, Salvado M, Morales M, Gamez J.
Haplotype Analysis of the First A4V-SOD1 Spanish Family: Two Separate Founders or a Single Common Founder?
Front Genet. 2019 Nov 8;10:1109.
DOI: 10.3389/fgene.2019.01109.
IF: 3.571
De la Casa-Fages B, Fernández-Eulate G, Gamez J, Barahona-Hernando R, Morís G, García-Barcina M, Infante J, Zulaica M, Fernández-Pelayo U, Muñoz-Oreja M, Urtasun M, Olaskoaga A, Zelaya V, Jericó I, Saez-Villaverde R, Catalina I, Sola E, Martínez-Sáez E, Pujol A, Ruiz M, Schlüter A, Spinazzola A, Muñoz-Blanco JL, Grandas F, Holt I, Álvarez V, López de Munaín A.
Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism.
Mov Disord. 2019 Oct;34(10):1547-1561.
DOI: 10.1002/mds.27812.
IF: 8.222
Borrego-Écija S, Cortés-Vicente E, Cervera-Carles L, Clarimón J, Gámez J, Batlle J, Ricken G, Molina-Porcel L, Aldecoa I, Sánchez-Valle R, Rojas-García R, Gelpi E.
Does ALS-FUS without FUS mutation represent ALS-FET? Report of three cases.
Neuropathol Appl Neurobiol. 2019 Jun;45(4):421-426.
DOI: 10.1111/nan.12527.
IF: 6.878

View all publications